{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,17]],"date-time":"2026-09-17T00:39:41Z","timestamp":1789605581605,"version":"build-2803163510"},"reference-count":47,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2005,3,1]],"date-time":"2005-03-01T00:00:00Z","timestamp":1109635200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Gynecologic Oncology"],"published-print":{"date-parts":[[2005,3]]},"DOI":"10.1016\/j.ygyno.2004.10.046","type":"journal-article","created":{"date-parts":[[2004,12,28]],"date-time":"2004-12-28T23:59:44Z","timestamp":1104278384000},"page":"705-713","source":"Crossref","is-referenced-by-count":64,"title":["Death receptors and ligands in cervical carcinogenesis: an immunohistochemical study"],"prefix":"10.1016","volume":"96","author":[{"given":"N.","family":"Reesink-Peters","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"B.M.T.","family":"Hougardy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"F.A.J.","family":"van den Heuvel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"K.A.","family":"ten Hoor","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"H.","family":"Hollema","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"H.M.","family":"Boezen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"E.G.E.","family":"de Vries","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"de Jong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.G.J.","family":"van der Zee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ygyno.2004.10.046_bib1","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1002\/ijc.1440","article-title":"Estimating the world cancer burden: Globocan 2000","volume":"94","author":"Parkin","year":"2001","journal-title":"Int. J. Cancer"},{"key":"10.1016\/j.ygyno.2004.10.046_bib2","first-page":"17","article-title":"Cervical human papillomavirus infection and intraepithelial neoplasia: a review","author":"Mitchell","year":"1996","journal-title":"J. Natl. Cancer Inst. Monogr."},{"key":"10.1016\/j.ygyno.2004.10.046_bib3","first-page":"F55","article-title":"Papillomavirus infections\u2014A major cause of human cancers","volume":"1288","author":"zur Hausen","year":"1996","journal-title":"Biochim. Biophys. Acta"},{"key":"10.1016\/j.ygyno.2004.10.046_bib4","doi-asserted-by":"crossref","first-page":"420","DOI":"10.1038\/nrc821","article-title":"Targeting death and decoy receptors of the tumour-necrosis factor superfamily","volume":"2","author":"Ashkenazi","year":"2002","journal-title":"Nat. Rev., Cancer"},{"key":"10.1016\/j.ygyno.2004.10.046_bib5","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1002\/path.1028","article-title":"Fas receptor-mediated apoptosis: a clinical application","volume":"196","author":"Timmer","year":"2002","journal-title":"J. Pathol."},{"key":"10.1016\/j.ygyno.2004.10.046_bib6","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1016\/S1359-6101(03)00029-7","article-title":"Apo2L\/TRAIL: apoptosis signaling, biology, and potential for cancer therapy","volume":"14","author":"Almasan","year":"2003","journal-title":"Cytokine Growth Factor Rev."},{"key":"10.1016\/j.ygyno.2004.10.046_bib7","first-page":"415","article-title":"Constitutive and induced expression of APO-1, a new member of the nerve growth factor\/tumor necrosis factor receptor superfamily, in normal and neoplastic cells","volume":"69","author":"Leithauser","year":"1993","journal-title":"Lab. Invest."},{"key":"10.1016\/j.ygyno.2004.10.046_bib8","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1002\/path.1364","article-title":"Expression of TRAIL (TNF-related apoptosis-inducing ligand) and its receptors in normal colonic mucosa, adenomas, and carcinomas","volume":"200","author":"Koornstra","year":"2003","journal-title":"J. Pathol."},{"key":"10.1016\/j.ygyno.2004.10.046_bib9","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1126\/science.276.5309.111","article-title":"The receptor for the cytotoxic ligand TRAIL","volume":"276","author":"Pan","year":"1997","journal-title":"Science"},{"key":"10.1016\/j.ygyno.2004.10.046_bib10","doi-asserted-by":"crossref","first-page":"815","DOI":"10.1126\/science.277.5327.815","article-title":"An antagonist decoy receptor and a death domain-containing receptor for TRAIL","volume":"277","author":"Pan","year":"1997","journal-title":"Science"},{"key":"10.1016\/j.ygyno.2004.10.046_bib11","doi-asserted-by":"crossref","first-page":"818","DOI":"10.1126\/science.277.5327.818","article-title":"Control of TRAIL-induced apoptosis by a family of signaling and decoy receptors","volume":"277","author":"Sheridan","year":"1997","journal-title":"Science"},{"key":"10.1016\/j.ygyno.2004.10.046_bib12","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1002\/j.1460-2075.1996.tb00351.x","article-title":"Involvement of Fas in regression of vaginal epithelia after ovariectomy and during an estrous cycle","volume":"15","author":"Suzuki","year":"1996","journal-title":"EMBO J."},{"key":"10.1016\/j.ygyno.2004.10.046_bib13","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1097\/00002371-200001000-00009","article-title":"Cervical cancer cells induce apoptosis of cytotoxic T lymphocytes","volume":"23","author":"Contreras","year":"2000","journal-title":"J. Immunother."},{"key":"10.1016\/j.ygyno.2004.10.046_bib14","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1159\/000326965","article-title":"Criteria for organized cervical screening programs. Special emphasis on the Netherlands program","volume":"46","author":"Hanselaar","year":"2002","journal-title":"Acta Cytol."},{"key":"10.1016\/j.ygyno.2004.10.046_bib15","series-title":"Atlas of tumor pathology","first-page":"37","article-title":"Tumors of the cervix, vagina and vulva; tumors of the cervix","author":"Kurman","year":"1992"},{"key":"10.1016\/j.ygyno.2004.10.046_bib16","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1002\/ijc.2910310104","article-title":"Production of a mouse monoclonal antibody reactive with a human nuclear antigen associated with cell proliferation","volume":"31","author":"Gerdes","year":"1983","journal-title":"Int. J. Cancer"},{"key":"10.1016\/j.ygyno.2004.10.046_bib17","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1046\/j.1525-1438.2000.010005417.x","article-title":"Expression of TRAIL (TNF-related apoptosis-inducing ligand) receptors in cervical cancer","volume":"10","author":"Ryu","year":"2000","journal-title":"Int. J. Gynecol. Cancer"},{"key":"10.1016\/j.ygyno.2004.10.046_bib18","series-title":"Blaustein's pathology of the female genital tract","first-page":"185","article-title":"Anatomy and histology of the cervix","author":"Ferenczy","year":"1994"},{"key":"10.1016\/j.ygyno.2004.10.046_bib19","doi-asserted-by":"crossref","first-page":"2013","DOI":"10.1002\/1097-0142(19940415)73:8<2013::AID-CNCR2820730802>3.0.CO;2-J","article-title":"Apoptosis. Its significance in cancer and cancer therapy","volume":"73","author":"Kerr","year":"1994","journal-title":"Cancer"},{"key":"10.1016\/j.ygyno.2004.10.046_bib20","doi-asserted-by":"crossref","first-page":"1150","DOI":"10.1016\/S0046-8177(98)90429-4","article-title":"Correlation of proliferation indices, apoptosis, and related oncogene expression (bcl-2 and c-erbB-2) and p53 in proliferative, hyperplastic, and malignant endometrium","volume":"29","author":"Ioffe","year":"1998","journal-title":"Hum. Pathol."},{"key":"10.1016\/j.ygyno.2004.10.046_bib21","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1002\/path.1711760107","article-title":"Role of apoptosis in modulation of the growth of human colorectal tubular and villous adenomas","volume":"176","author":"Arai","year":"1995","journal-title":"J. Pathol."},{"key":"10.1016\/j.ygyno.2004.10.046_bib22","first-page":"54","article-title":"Progressive increase of apoptosis in prostatic intraepithelial neoplasia and carcinoma: comparison between in situ end-labeling of fragmented DNA and detection by routine hematoxylin-eosin staining","volume":"121","author":"Drachenberg","year":"1997","journal-title":"Arch. Pathol. Lab. Med."},{"key":"10.1016\/j.ygyno.2004.10.046_bib23","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1053\/hupa.2002.32226","article-title":"Apoptosis and apoptosis-associated parameters in relation to tamoxifen exposure in postmenopausal endometrium","volume":"33","author":"Mourits","year":"2002","journal-title":"Hum. Pathol."},{"key":"10.1016\/j.ygyno.2004.10.046_bib24","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1034\/j.1600-0463.2000.d01-46.x","article-title":"Expression of topoisomerase II and Ki-67 in cervical carcinoma-clinicopathological study using immunohistochemistry","volume":"108","author":"Davidson","year":"2000","journal-title":"APMIS"},{"key":"10.1016\/j.ygyno.2004.10.046_bib25","doi-asserted-by":"crossref","first-page":"376","DOI":"10.1016\/S0090-8258(03)00061-1","article-title":"Changes in the topological expression of markers of differentiation and apoptosis in defined stages of human cervical dysplasia and carcinoma","volume":"89","author":"Zanotti","year":"2003","journal-title":"Gynecol. Oncol."},{"key":"10.1016\/j.ygyno.2004.10.046_bib26","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1023\/A:1015312119693","article-title":"Molecular mechanisms of \u201cdetachment-induced apoptosis-Anoikis\u201d","volume":"7","author":"Grossmann","year":"2002","journal-title":"Apoptosis"},{"key":"10.1016\/j.ygyno.2004.10.046_bib27","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1016\/S1040-8428(01)00228-1","article-title":"Changes in apoptosis during the development of colorectal cancer: a systematic review of the literature","volume":"45","author":"Koornstra","year":"2003","journal-title":"Crit. Rev. Oncol.\/Hematol."},{"key":"10.1016\/j.ygyno.2004.10.046_bib28","doi-asserted-by":"crossref","first-page":"1743","DOI":"10.1038\/bjc.1996.624","article-title":"What is an apoptotic index measuring? A commentary","volume":"74","author":"Potten","year":"1996","journal-title":"Br. J. Cancer"},{"key":"10.1016\/j.ygyno.2004.10.046_bib29","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1111\/j.1365-2559.2004.01739.x","article-title":"Assessment of apoptosis by M30 immunoreactivity and the correlation with morphological criteria in normal colorectal mucosa, adenomas and carcinomas","volume":"44","author":"Koornstra","year":"2004","journal-title":"Histopathology"},{"key":"10.1016\/j.ygyno.2004.10.046_bib30","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1016\/S0090-8258(03)00053-2","article-title":"HPV subtypes and immunological parameters of cervical cancer in Iceland during two time periods, 1958\u20131960 and 1995\u20131996","volume":"89","author":"Mikaelsdottir","year":"2003","journal-title":"Gynecol. Oncol."},{"key":"10.1016\/j.ygyno.2004.10.046_bib31","first-page":"2057","article-title":"Up-regulation of Fas (APO-1\/CD95) ligand and down-regulation of Fas expression in human esophageal cancer","volume":"58","author":"Gratas","year":"1998","journal-title":"Cancer Res."},{"key":"10.1016\/j.ygyno.2004.10.046_bib32","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1002\/sita.200300022","article-title":"The Fas ligand as a cell death factor and signal transducer","volume":"3","author":"Linkermann","year":"2003","journal-title":"Signal Transduct."},{"key":"10.1016\/j.ygyno.2004.10.046_bib33","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1038\/25387","article-title":"Genomic amplification of a decoy receptor for Fas ligand in lung and colon cancer","volume":"396","author":"Pitti","year":"1998","journal-title":"Nature"},{"key":"10.1016\/j.ygyno.2004.10.046_bib34","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1016\/S0090-8258(03)00206-3","article-title":"Fas ligand expression in cervical adenocarcinoma. Relevance to lymph node metastasis and tumor progression","volume":"90","author":"Kase","year":"2003","journal-title":"Gynecol. Oncol."},{"key":"10.1016\/j.ygyno.2004.10.046_bib35","doi-asserted-by":"crossref","first-page":"11128","DOI":"10.1128\/JVI.75.22.11128-11136.2001","article-title":"Induction of cell death in human immunodeficiency virus-infected macrophages and resting memory CD4 T cells by TRAIL\/Apo2l","volume":"75","author":"Lum","year":"2001","journal-title":"J. Virol."},{"key":"10.1016\/j.ygyno.2004.10.046_bib36","doi-asserted-by":"crossref","first-page":"659","DOI":"10.1053\/gast.2002.31889","article-title":"TRAIL and its receptors in the colonic epithelium: a putative role in the defense of viral infections","volume":"122","author":"Str\u00e4ter","year":"2002","journal-title":"Gastroenterology"},{"key":"10.1016\/j.ygyno.2004.10.046_bib37","doi-asserted-by":"crossref","first-page":"2246","DOI":"10.1002\/1521-4141(200208)32:8<2246::AID-IMMU2246>3.0.CO;2-6","article-title":"Characterization of the in vivo function of TNF-alpha-related apoptosis-inducing ligand, TRAIL\/Apo2L, using TRAIL\/Apo2L gene-deficient mice","volume":"32","author":"Sedger","year":"2002","journal-title":"Eur. J. Immunol."},{"key":"10.1016\/j.ygyno.2004.10.046_bib38","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1084\/jem.20011171","article-title":"Critical role for tumor necrosis factor-related apoptosis-inducing ligand in immune surveillance against tumor development","volume":"195","author":"Takeda","year":"2002","journal-title":"J. Exp. Med."},{"key":"10.1016\/j.ygyno.2004.10.046_bib39","doi-asserted-by":"crossref","first-page":"821","DOI":"10.1369\/jhc.3A6112.2004","article-title":"Tissue distribution of the death ligand TRAIL and its receptors","volume":"52","author":"Spierings","year":"2004","journal-title":"J. Histochem. Cytochem."},{"key":"10.1016\/j.ygyno.2004.10.046_bib40","first-page":"95","article-title":"Modulation of death receptor pathways in oncology","volume":"39","author":"de Vries","year":"2003","journal-title":"Drugs Today (Barc)"},{"key":"10.1016\/j.ygyno.2004.10.046_bib41","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1016\/S0014-5793(00)02042-1","article-title":"Mechanisms of resistance of normal cells to TRAIL induced apoptosis vary between different cell types","volume":"482","author":"Zhang","year":"2000","journal-title":"FEBS Lett."},{"key":"10.1016\/j.ygyno.2004.10.046_bib42","doi-asserted-by":"crossref","first-page":"786","DOI":"10.1002\/ijc.20041","article-title":"Aberrant methylation of trail decoy receptor genes is frequent in multiple tumor types","volume":"109","author":"Shivapurkar","year":"2004","journal-title":"Int. J. Cancer"},{"key":"10.1016\/j.ygyno.2004.10.046_bib43","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1172\/JCI6926","article-title":"Safety and antitumor activity of recombinant soluble Apo2 ligand","volume":"104","author":"Ashkenazi","year":"1999","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.ygyno.2004.10.046_bib44","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1016\/j.coph.2004.02.006","article-title":"Targeting death receptors in cancer with Apo2L\/TRAIL","volume":"4","author":"Kelley","year":"2004","journal-title":"Curr. Opin. Pharmacol."},{"key":"10.1016\/j.ygyno.2004.10.046_bib45","doi-asserted-by":"crossref","first-page":"3060","DOI":"10.1200\/jco.2004.22.14_suppl.3060","article-title":"A phase 1 and pharmacokinetic study of HGS-ETR1(TRM-1), a human monoclonal agonist-antibody to TRAIL-R1, in patients with advanced solid tumors","volume":"22","author":"Tolcher","year":"2004","journal-title":"Proc. Am. Soc. Clin. Oncol."},{"key":"10.1016\/j.ygyno.2004.10.046_bib46","doi-asserted-by":"crossref","first-page":"2533","DOI":"10.1200\/jco.2004.22.14_suppl.2533","article-title":"Phase 1 study of a fully human monoclonal antibody to the tumor necrosis factor-related apoptosis-inducing ligand death receptor 4 (TRAIL-R1) in subjects with advanced solid malignancies or non-Hodgkin's lymphoma (NHL)","volume":"22","author":"Le","year":"2004","journal-title":"Proc. Am. Soc. Clin. Oncol."},{"key":"10.1016\/j.ygyno.2004.10.046_bib47","doi-asserted-by":"crossref","first-page":"6595","DOI":"10.1200\/jco.2004.22.14_suppl.6595","article-title":"Selective agonistic monoclonal antibodies to the TRAIL receptors R1 and R2 induce cell death and potentiate the effect of chemotherapy and bortezomib in primary and cultured lymphoma cells","volume":"22","author":"Georgakis","year":"2004","journal-title":"Proc. Am. Soc. Clin. Oncol."}],"container-title":["Gynecologic Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0090825804008297?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0090825804008297?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,1,30]],"date-time":"2019-01-30T15:23:49Z","timestamp":1548861829000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0090825804008297"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2005,3]]},"references-count":47,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2005,3]]}},"alternative-id":["S0090825804008297"],"URL":"https:\/\/doi.org\/10.1016\/j.ygyno.2004.10.046","relation":{},"ISSN":["0090-8258"],"issn-type":[{"value":"0090-8258","type":"print"}],"subject":[],"published":{"date-parts":[[2005,3]]}}}